The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 18 of the 29 sources its claims cite were checked for support.
Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy
Open accessAbstract
Suspected meningitis/encephalitis cases require prompt empirical antimicrobial therapy. Syndromic diagnostics like the FilmArray Meningitis/Encephalitis (FAME) panel offer rapid results and are increasingly used despite high costs. This study assessed FAME's integration in clinical microbiology laboratories' everyday practice and its impact on early treatment decisions. The FilmArray Meningitis/encephalitis panel Outcome Study (FAMOuS) retrospectively reviewed biological data, treatments before/after FAME, and outcomes from 783 patients across six French hospitals over a 3-year period. FAME results were 80% negative, 7% bacterial, and 13% viral, with no bacterial false negatives. Positive results in samples with <10 leukocytes were exclusively seen in immunocompromised individuals and children under 2. Positive results prompted therapeutic changes in 74% of cases, compared to 50% for negatives. FAMOuS enabled the proposal of a decision-support flowchart to optimize the rational use of FAME and support antibiotic stewardship, with the potential to increase early antibiotic discontinuation and reduce unnecessary testing.IMPORTANCEPrompt identification of infectious causes is essential in suspected meningitis and encephalitis, where timely treatment decisions can be lifesaving. The FAMOuS study evaluated the use of the FilmArray Meningitis/Encephalitis (FAME) panel across six French hospitals, analyzing nearly 800 patient episodes. The findings demonstrate that FAME offers reliable results that directly influence clinical management-guiding therapeutic adjustments in most positive cases and supporting early antibiotic discontinuation when appropriate. The study highlights specific patient contexts where FAME provides the greatest clinical value and proposes a decision-support flowchart to optimize its rational use. By integrating rapid molecular diagnostics into everyday practice, this work contributes to improved patient care and reinforces hospital antibiotic stewardship strategies.
Overview
CoChat Summary
## TL;DR
This retrospective multicenter study of 783 patients across six French hospitals found that the FilmArray Meningitis/Encephalitis (FAME) panel was mostly negative (80%) and could support early antimicrobial de-escalation, especially when combined with CSF WBC and lactate results. The authors propose a flowchart to target testing and improve antibiotic stewardship, but note that prospective validation is still needed.
## Key findings
- Among 786 patients tested, 3 invalid tests were excluded; of the 783 evaluable samples, FAME was 80% negative, 7% bacterial positive (n = 55), 13% viral positive (n = 100), and 1 sample positive for Cryptococcus.
- No bacterial false negatives were reported in the abstract; in the results, one negative FAME corresponded to an H. influenzae culture considered laboratory contamination, while 10 true meningitis cases were FAME-positive but culture-negative.
- CSF markers were strongly associated with bacterial FAME positivity: bacterial cases had median CSF WBC 1,530 vs 135 in viral and 17 in negative cases, and median CSF lactate 11.6 mmol/L vs 2.3 and 2.4 mmol/L.
- In treated patients with negative direct examination, a negative FAME led to de-escalation in 25% and no impact in 71%; after excluding untreated patients, de-escalation rose to 50% for negative FAME and 74% overall for positive FAME results.
- CSF lactate ROC analysis identified an optimal bacterial-infection cutoff of 6.6 mmol/L; the authors state that <3.2 mmol/L supports early antibiotic discontinuation when FAME is negative.
## Methods
- Retrospective multicenter cohort (FAMOuS) of patients of any age from six French tertiary hospitals who underwent FAME on lumbar puncture between January 2019 and December 2022.
- Collected data included demographics, hospitalization unit, immunodepression status, CSF biochemistry and microbiology, FAME result, dexamethasone use, hospital-acquired vs community-acquired status, targeted antibiotics/antivirals before and within 24 h after FAME, length of stay, and 30-day death.
- Analysis used descriptive statistics, group comparisons (χ²/Fisher, t-test/Mann–Whitney), and univariate/multivariate conditional logistic regression to identify correlates of FAME positivity; ROC analysis was used for CSF lactate thresholds.
## Limitations
- The paper explicitly states limitations: retrospective design, heterogeneity of inclusion across centers, incomplete lactate measurements in some patients, and lack of independent adjudication of therapeutic decisions.
- Evident from the text: clinical symptoms such as headache, fever, photophobia, phonophobia, and neck stiffness were not collected, so clinical presentation could not be directly analyzed.
- Evident from the text: the proposed flowchart was not prospectively validated, and the authors call for independent prospective evaluation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
10 Valid · 1 Not valid · 3 Not checked · 47 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Median times to pathogen identification with standard techniques have been reported near 96 h, a critical window during which unnecessary antimicrobial exposure can increase adverse events and the risk of colonization by resistant organisms (3–5).”
§ Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy > INTRODUCTION Meningitis and encephalitis (ME) remain major global health problems with significant morbidity and mortality and constitute medical emergencies in which rapid etiological diagnosis and early antimicrobial treatment are essential (1, 2). Conventional microbiological methods are specific but often lack sensitivity after prior antibiotic exposure and require prolonged processing times, which force clinicians to initiate or maintain empirical broad-spectrum therapy while awaiting results. Median times to pathogen identification with standard techniques have been reported near 96 h, a critical window during which unnecessary antimicrobial exposure can increase adverse events and the risk of colonization by resistant organisms (3–5). Syndromic molecular testing, such as the FilmArray Meningitis/Encephalitis (FAME) panel (bioMérieux, France), performs multiplex PCR for 14 pathogens on cerebrospinal fluid (CSF) and reduces median time to identification to approximately 2 h (3, 6). Despite high reported sensitivity and specificity for common targets, the FAME panel raises practical issues related to cost, incomplete organism coverage, and the need to interpret results in a clinical context (6, 7). Published work shows mixed effects on clinical outcomes: reductions in hospital length of stay in adults and decreases in antimicrobial duration mainly in pediatric cohorts (8). Overall, randomized trials evaluating the FAME and, hence, high-quality evidence are lacking. Evidence is still confined to observational, usually retrospective, and single-center studies (9). Current guidelines therefore recommend targeted PCRs in specific situations rather than routine syndromic testing (10–14). The aims of our retrospective multicenter study were to establish evidence-based criteria for targeted FAME use and to evaluate the panel’s early impact on therapeutic decision-making, with particular emphasis on antimicrobial stewardship.
What the sources say
- Supportedcites [3] source
The Results section reports a median time to pathogen identification of 96 hours with conventional methods, matching the attributed claim. This figure comes from the study’s patients with meningitis or encephalitis. (LLM, conf=0.95)
- Could not verifycites [4] sourceExperimental — accuracy not yet measured
The passages from “Species and community determinants of susceptibility during antibiotic exposure” discuss susceptibility testing, but give no time to pathogen identification. Searches for a 96-hour median and diagnostic turnaround time found no passage addressing that figure. Page numbers were not available in our copy. (LLM, conf=0.73)
- Could not verifycites [5] sourceExperimental — accuracy not yet measured
The Results section discusses antibiotic duration and resistant-bacteria carriage, but does not report a time to pathogen identification. Searches for “96 h” and conventional microbiology turnaround time found no supporting passage in our copy; page numbers were unavailable. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Evidence is still confined to observational, usually retrospective, and single-center studies (9).”
§ Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy > INTRODUCTION Meningitis and encephalitis (ME) remain major global health problems with significant morbidity and mortality and constitute medical emergencies in which rapid etiological diagnosis and early antimicrobial treatment are essential (1, 2). Conventional microbiological methods are specific but often lack sensitivity after prior antibiotic exposure and require prolonged processing times, which force clinicians to initiate or maintain empirical broad-spectrum therapy while awaiting results. Median times to pathogen identification with standard techniques have been reported near 96 h, a critical window during which unnecessary antimicrobial exposure can increase adverse events and the risk of colonization by resistant organisms (3–5). Syndromic molecular testing, such as the FilmArray Meningitis/Encephalitis (FAME) panel (bioMérieux, France), performs multiplex PCR for 14 pathogens on cerebrospinal fluid (CSF) and reduces median time to identification to approximately 2 h (3, 6). Despite high reported sensitivity and specificity for common targets, the FAME panel raises practical issues related to cost, incomplete organism coverage, and the need to interpret results in a clinical context (6, 7). Published work shows mixed effects on clinical outcomes: reductions in hospital length of stay in adults and decreases in antimicrobial duration mainly in pediatric cohorts (8). Overall, randomized trials evaluating the FAME and, hence, high-quality evidence are lacking. Evidence is still confined to observational, usually retrospective, and single-center studies (9). Current guidelines therefore recommend targeted PCRs in specific situations rather than routine syndromic testing (10–14). The aims of our retrospective multicenter study were to establish evidence-based criteria for targeted FAME use and to evaluate the panel’s early impact on therapeutic decision-making, with particular emphasis on antimicrobial stewardship.
What the sources say
- Could not verifycites [9] sourceExperimental — accuracy not yet measured
The Meningitis/Encephalitis Panel section discusses FAMEP findings and cites a meta-analysis, but does not characterize the underlying studies as observational, retrospective, or single-center. Searches for those study-design terms and for limitations of FAMEP evidence found no passage establishing the claim. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We recommend reserving first-line FAME use to community-acquired ME and performing the panel systematically in immunocompromised patients and in children under 2 years, regardless of CSF WBC, because pleocytosis may be absent in these groups (20–22).”
§ Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy > DISCUSSION Syndromic panels like FAME offer dramatically faster results and high performance for included targets but present dilemmas of cost, incomplete coverage, and interpretative challenges, notably with positive HHV-6 in non-immunocompromised patients and H. influenzae false positive (16–18). Current guideline recommendations for targeted PCR after negative direct examination may delay diagnosis when specific PCRs are not continuously available. In our cohort, such an approach would have missed 10 (18%) bacterial meningitis cases caused by H. influenzae, S. agalactiae, and E. coli K1 (10–14). Conversely, indiscriminate use of FAME is costly and sometimes non-contributive. As laboratories cannot sustain multiple molecular techniques for cost reasons, syndromic PCR panels, which allow random-access testing and are well suited to emergency diagnostics, represent a practical alternative when used judiciously and in appropriate clinical contexts. The FAMOuS study included 783 patients who underwent FAME, and we reviewed biological data, treatments before/after FAME, and outcomes to assess integration in clinical microbiology laboratories and impact on early treatment decisions. Clinical data, such as headaches, photophobia, phonophobia, fever, or neck stiffness, were not collected for several reasons: (i) the clinical presentation can vary significantly from one patient to another, can be difficult to assess objectively, and may even be absent in some cases (19), (ii) there was a high risk of bias due to the retrospective nature of data collection, and (iii) gathering this information was beyond the scope of our study, as we focused on obtaining FAME results after the lumbar puncture, following the clinical suspicion of ME. By combining our data with literature thresholds, we propose a pragmatic, cost-conscious decision tree to concentrate FAME testing where it most increases diagnostic yield and where its rapid results can safely drive early discontinuation of unnecessary antibiotics (Fig. 4). We recommend reserving first-line FAME use to community-acquired ME and performing the panel systematically in immunocompromised patients and in children under 2 years, regardless of CSF WBC, because pleocytosis may be absent in these groups (20–22). For other patients, a CSF WBC threshold of ≥10/mm3, as proposed in several studies, identifies those with a higher likelihood of panel-detectable infection (23, 24); WBC <10/mm3 generally yields no bacterial detection and should not prompt routine FAME testing for bacterial meningitis, especially with no biochemistry abnormalities (25). Given FAME’s limited sensitivity for HSV, the absence of pleocytosis in some viral infections, and the possibility of early false-negative HSV PCR results, it remains essential to perform specific viral PCRs, notably repeating testing around day 4 after symptom onset (7, 26–28). Traumatic lumbar puncture can spuriously raise CSF WBC, so the white cell-to-red cell ratio may help interpret cytology and guide the use of FAME testing (29); nevertheless, we observed FAME positives even with very high RBC counts. The data did not allow for determining whether FAME detected organisms originating from blood, but concordant positive FAME and CSF cultures in some cases support true meningitis rather than isolated bacteremia. CSF lactate provides an independent and strong discriminator: values above 6.6 mmol/L indicate a high probability of bacterial infection and warrant continuation or adaptation of empiric antibiotics, whereas values below 3.2 mmol/L support early antibiotic discontinuation when FAME is negative (30, 31).
What the sources say
- Partly supportedcites [20] sourceExperimental — accuracy not yet measured
The Abstract reports normal CSF leukocyte counts in some adults with bacterial meningitis and a higher proportion of immunocompromising conditions in that group. The study examined adults, so it does not support the claim about children under 2. Page numbers were not supplied for these passages. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [21] source
- Supportedcites [22] source
The Discussion reports meningitis without CSF pleocytosis in pediatric patients and describes immunocompromised patients who may not mount a leukocyte response. The Methods include infants aged 28 days or younger and 29–56 days, supporting the claim that pleocytosis may be absent in children under 2. The paper does not evaluate the citing authors’ separate recommendation to use the FAME panel systematically. (LLM, conf=0.89)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“For other patients, a CSF WBC threshold of ≥10/mm3, as proposed in several studies, identifies those with a higher likelihood of panel-detectable infection (23, 24); WBC <10/mm3 generally yields no bacterial detection and should not prompt routine FAME testing for bacterial meningitis, especially with no biochemistry abnormalities (25).”
§ Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy > DISCUSSION Syndromic panels like FAME offer dramatically faster results and high performance for included targets but present dilemmas of cost, incomplete coverage, and interpretative challenges, notably with positive HHV-6 in non-immunocompromised patients and H. influenzae false positive (16–18). Current guideline recommendations for targeted PCR after negative direct examination may delay diagnosis when specific PCRs are not continuously available. In our cohort, such an approach would have missed 10 (18%) bacterial meningitis cases caused by H. influenzae, S. agalactiae, and E. coli K1 (10–14). Conversely, indiscriminate use of FAME is costly and sometimes non-contributive. As laboratories cannot sustain multiple molecular techniques for cost reasons, syndromic PCR panels, which allow random-access testing and are well suited to emergency diagnostics, represent a practical alternative when used judiciously and in appropriate clinical contexts. The FAMOuS study included 783 patients who underwent FAME, and we reviewed biological data, treatments before/after FAME, and outcomes to assess integration in clinical microbiology laboratories and impact on early treatment decisions. Clinical data, such as headaches, photophobia, phonophobia, fever, or neck stiffness, were not collected for several reasons: (i) the clinical presentation can vary significantly from one patient to another, can be difficult to assess objectively, and may even be absent in some cases (19), (ii) there was a high risk of bias due to the retrospective nature of data collection, and (iii) gathering this information was beyond the scope of our study, as we focused on obtaining FAME results after the lumbar puncture, following the clinical suspicion of ME. By combining our data with literature thresholds, we propose a pragmatic, cost-conscious decision tree to concentrate FAME testing where it most increases diagnostic yield and where its rapid results can safely drive early discontinuation of unnecessary antibiotics (Fig. 4). We recommend reserving first-line FAME use to community-acquired ME and performing the panel systematically in immunocompromised patients and in children under 2 years, regardless of CSF WBC, because pleocytosis may be absent in these groups (20–22). For other patients, a CSF WBC threshold of ≥10/mm3, as proposed in several studies, identifies those with a higher likelihood of panel-detectable infection (23, 24); WBC <10/mm3 generally yields no bacterial detection and should not prompt routine FAME testing for bacterial meningitis, especially with no biochemistry abnormalities (25). Given FAME’s limited sensitivity for HSV, the absence of pleocytosis in some viral infections, and the possibility of early false-negative HSV PCR results, it remains essential to perform specific viral PCRs, notably repeating testing around day 4 after symptom onset (7, 26–28). Traumatic lumbar puncture can spuriously raise CSF WBC, so the white cell-to-red cell ratio may help interpret cytology and guide the use of FAME testing (29); nevertheless, we observed FAME positives even with very high RBC counts. The data did not allow for determining whether FAME detected organisms originating from blood, but concordant positive FAME and CSF cultures in some cases support true meningitis rather than isolated bacteremia. CSF lactate provides an independent and strong discriminator: values above 6.6 mmol/L indicate a high probability of bacterial infection and warrant continuation or adaptation of empiric antibiotics, whereas values below 3.2 mmol/L support early antibiotic discontinuation when FAME is negative (30, 31).
What the sources say
- Supportedcites [23] source
The Results (Study population and pathogen detection; page not supplied) report higher viral and bacterial positivity among samples above the 10 leukocytes/mm3 threshold. The Results (Comparative analysis for bacterial pathogens; page not supplied) also report that applying a threshold of 10/mm3 raised the FilmArray positive predictive value for bacterial detection from 58% to 87%. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [24] source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In our cohort, such an approach would have missed 10 (18%) bacterial meningitis cases caused by H. influenzae, S. agalactiae, and E. coli K1 (10–14).”
§ Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy > DISCUSSION Syndromic panels like FAME offer dramatically faster results and high performance for included targets but present dilemmas of cost, incomplete coverage, and interpretative challenges, notably with positive HHV-6 in non-immunocompromised patients and H. influenzae false positive (16–18). Current guideline recommendations for targeted PCR after negative direct examination may delay diagnosis when specific PCRs are not continuously available. In our cohort, such an approach would have missed 10 (18%) bacterial meningitis cases caused by H. influenzae, S. agalactiae, and E. coli K1 (10–14). Conversely, indiscriminate use of FAME is costly and sometimes non-contributive. As laboratories cannot sustain multiple molecular techniques for cost reasons, syndromic PCR panels, which allow random-access testing and are well suited to emergency diagnostics, represent a practical alternative when used judiciously and in appropriate clinical contexts. The FAMOuS study included 783 patients who underwent FAME, and we reviewed biological data, treatments before/after FAME, and outcomes to assess integration in clinical microbiology laboratories and impact on early treatment decisions. Clinical data, such as headaches, photophobia, phonophobia, fever, or neck stiffness, were not collected for several reasons: (i) the clinical presentation can vary significantly from one patient to another, can be difficult to assess objectively, and may even be absent in some cases (19), (ii) there was a high risk of bias due to the retrospective nature of data collection, and (iii) gathering this information was beyond the scope of our study, as we focused on obtaining FAME results after the lumbar puncture, following the clinical suspicion of ME. By combining our data with literature thresholds, we propose a pragmatic, cost-conscious decision tree to concentrate FAME testing where it most increases diagnostic yield and where its rapid results can safely drive early discontinuation of unnecessary antibiotics (Fig. 4). We recommend reserving first-line FAME use to community-acquired ME and performing the panel systematically in immunocompromised patients and in children under 2 years, regardless of CSF WBC, because pleocytosis may be absent in these groups (20–22). For other patients, a CSF WBC threshold of ≥10/mm3, as proposed in several studies, identifies those with a higher likelihood of panel-detectable infection (23, 24); WBC <10/mm3 generally yields no bacterial detection and should not prompt routine FAME testing for bacterial meningitis, especially with no biochemistry abnormalities (25). Given FAME’s limited sensitivity for HSV, the absence of pleocytosis in some viral infections, and the possibility of early false-negative HSV PCR results, it remains essential to perform specific viral PCRs, notably repeating testing around day 4 after symptom onset (7, 26–28). Traumatic lumbar puncture can spuriously raise CSF WBC, so the white cell-to-red cell ratio may help interpret cytology and guide the use of FAME testing (29); nevertheless, we observed FAME positives even with very high RBC counts. The data did not allow for determining whether FAME detected organisms originating from blood, but concordant positive FAME and CSF cultures in some cases support true meningitis rather than isolated bacteremia. CSF lactate provides an independent and strong discriminator: values above 6.6 mmol/L indicate a high probability of bacterial infection and warrant continuation or adaptation of empiric antibiotics, whereas values below 3.2 mmol/L support early antibiotic discontinuation when FAME is negative (30, 31).
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The CSF PCR section says that 16S PCR may be used when pathogen-specific PCR does not identify an organism, supporting the general limitation of a targeted approach. The guideline does not report the citing authors’ cohort, the 10 (18%) missed cases, or that those cases were caused by the three named organisms; those are presented as the citing authors’ own findings. (LLM, conf=0.78)
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
Table 6 (Etiologic Agents; page unavailable) lists H. influenzae, S. agalactiae, and E. coli as bacterial meningitis agents. The guide does not evaluate the targeted PCR approach or establish which organisms it would miss. The 10 cases (18%) are presented as the citing authors’ own cohort result, not as a finding from this guide. (LLM, conf=0.79)
- Not checked — no full text of the sourcecites [12] source
- Not matchedcites [13]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [14] source
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
21 more claims
Create a free account to see all 61 claims and every source verdict.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 27
Citations
Cites
ESCMID guideline: diagnosis and treatment of acute bacterial meningitis
van de Beek, D., Cabellos, C., Dzupova, O., Esposito, S., Klein, M., Kloek, A. T., Leib, S. L., Mourvillier, B., Ostergaard, C., Pagliano, P., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.01.007 · Cited by 919
Self-citationMiller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gilligan, P. H., Gonzalez, M. D., Jerris, R. C., Kehl, S. C., Patel, R., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy381 · Cited by 641
Antibiotic perturbations to the gut microbiome
Fishbein, S. R. S., Mahmud, B., & Dantas, G. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00933-y · Cited by 440
Dilemmas in the diagnosis of acute community-acquired bacterial meningitis
Brouwer, M. C., Thwaites, G. E., Tunkel, A. R., & van de Beek, D. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61185-4 · Cited by 302 · cited 1×
“…presentation can vary significantly from one patient to another, can be difficult to assess objectively, and may even be absent in some cases (19), (ii) there was a high risk of bias due to the retrospective nature of data collection, and (iii) gathering this information was beyond the scope…”
McGill, F., Heyderman, R. S., Michael, B. D., Defres, S., Beeching, N. J., Borrow, R., Glennie, L., Gaillemin, O., Wyncoll, D., Kaczmarski, E., et al. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.01.007 · Cited by 254 · cited 1×
“Current guidelines therefore recommend targeted PCRs in specific situations rather than routine syndromic testing (10–14).”
Weil, A. A., Glaser, C. A., Amad, Z., & Forghani, B. (2002) · Clinical Infectious Diseases · doi:10.1086/339550 · Cited by 254
Sakushima, K., Hayashino, Y., Kawaguchi, T., Jackson, J. L., & Fukuhara, S. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.02.010 · Cited by 246 · cited 1×
“…provides an independent and strong discriminator: values above 6.6 mmol/L indicate a high probability of bacterial infection and warrant continuation or adaptation of empiric antibiotics, whereas values below 3.2 mmol/L support early antibiotic discontinuation when FAME is negative (30, 31).”
InfluentialElaboration of a consensual definition of de-escalation allowing a ranking of β-lactams
Weiss, E., Zahar, J.-R., Lesprit, P., Ruppe, E., Leone, M., Chastre, J., Lucet, J.-C., Paugam-Burtz, C., Brun-Buisson, C., Timsit, J.-F., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.03.013 · Cited by 180 · cited 2×
“Conversely, therapeutic escalation was characterized by an increase in the number of antibiotics or a broadening of the β-lactam spectrum according to Weiss et al. (15).”
Trujillo-Gómez, J., Tsokani, S., Arango-Ferreira, C., Atehortúa-Muñoz, S., Jimenez-Villegas, M. J., Serrano-Tabares, C., Veroniki, A.-A., & Florez, I. D. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101275 · Cited by 139
Green, D. A., Pereira, M., Miko, B., Radmard, S., Whittier, S., & Thakur, K. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy288 · Cited by 110 · cited 1×
“Bacteria-positive FAME cases exhibited markedly higher CSF WBC counts than virus-pos itive cases and negative cases (median = 1,530 [2–21,000] vs 135 [2–2,300] and 17 [1– 12,700], P 0.0001).”
Influential
Cited by
Agrawal, A., Shukla, D. P., Thanneeru, S. K., Sharma, P. K., Chanchlani, R., Kumar, A., Joshi, R., Singh, J., & Rukadikar, C. A. (2026) · Cureus · doi:10.7759/cureus.114618
Metadata
- Authors
- Nicolau-Guillaumet, N., Moutel, M., Plouzeau-Jayle, C., Pean de Ponfilly, G., Courbin, V., Ranc, A.-G., Revillet, H., Mourvillier, B., Hentzien, M., Muggeo, A., Guillard, T., & On behalf of the GMC Study Group
- Affiliations
- Inserm (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Service de Microbiologie Clinique, Hôpitaux Paris Saint-Joseph and Marie-Lannelongue
- Hôpital d'Instruction des Armées Bégin (FR)
- Hospices Civils de Lyon (FR)
- Service de Bactériologie-Hygiène Hospitalière, CHU de Toulouse, Hôpital Purpan, Institut de Recherche en Santé Digestive (IRSD), Université de Toulouse, INSERM, INRAE, ENVT, UPS
- Corresponding author
- Guillard, Thomas
- ORCID
- Venue
- Microbiology Spectrum
- Publisher
- American Society for Microbiology
- Published
- 2026-06-02
- Volume
- 14
- Issue
- 6
- Pages
- e0056626-e0056626
- ISSN
- 2165-0497 (ISSN-L)
- PMC
- PMC13227975
- OpenAlex
- W7160383516
- Cited by
- 1
- References
- 29
- Citations by year
- 2026: 1
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Microbiology Spectrum (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
- Keywords
- FilmArray Meningitis/Encephalitis panel, meningitis, encephalitis, antibiotic stewardship, molecular diagnosis, empirical antimicrobial therapy, decision support, immunocompromised patients, children, unnecessary testing
- MeSH terms
- Antimicrobial Stewardship, Anti-Bacterial Agents, Child, Child, Preschool, Encephalitis, Female, France, Humans, Infant, Male, Meningitis, Retrospective Studies, Molecular Diagnostic Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy. https://app.cochat.ai/papers/10.1128/spectrum.00566-26
- The paper
- Nicolau-Guillaumet, N., Moutel, M., Plouzeau-Jayle, C., Pean de Ponfilly, G., Courbin, V., Ranc, A.-G., Revillet, H., Mourvillier, B., Hentzien, M., Muggeo, A., Guillard, T., & On behalf of the GMC Study Group. (2026). Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00566-26
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.